Unspecified

Extract from the above information

This product is a fluoroquinolone antibacterial drug, which has antibacterial effects on Gram-negative bacteria (such as Escherichia coli, Klebsiella pneumoniae, Proteus, etc.) and some Gram-positive cocci (such as Staphylococcus, hemolytic Streptococcus). Its mechanism of action is to inhibit the DNA gyrase of bacteria to achieve bactericidal effect.

Semi-synthetic broad-spectrum fungicide, with strong antibacterial activity against Mycobacterium tuberculosis, 2 to 10 times stronger than rifampicin; its anti-tuberculosis effect in mice is also better than rifampicin. It is sensitive to Mycobacterium leprae and other mycobacteria such as Mycobacterium kansasii and Mycobacterium toad, has high antibacterial activity against most Gram-positive cocci, and has poor effect on Gram-negative bacteria. Its effect on Chlamydia is similar to that of erythromycin and doxycycline, but worse than that of rifampicin; it has poor effect on methicillin-resistant Staphylococcus. The mechanism of action is to firmly bind to the subunits of DNA-dependent RNA polymerase, inhibit the synthesis of bacterial RNA, prevent the enzyme from connecting to DNA, thereby blocking the RNA transcription process and stopping the synthesis of DNA and protein.

Semi-synthetic broad-spectrum bactericide, it has strong antibacterial activity against Mycobacterium tuberculosis in vitro, with a minimum inhibitory concentration (MIC) of 0.12-0.25 mg/L, which is 2-10 times stronger than rifampicin; its anti-tuberculosis infection effect in mice is also better than rifampicin. Mycobacterium leprae and other mycobacteria such as Mycobacterium kansasii and Mycobacterium toad are also sensitive to this product, but Mycobacterium avium is resistant. It has high antibacterial activity against most Gram-positive cocci, with a MIC of 0.025 mg/L; it has poor effect on Gram-negative bacteria. Its effect on Chlamydia is similar to that of erythromycin and doxycycline, which is worse than rifampicin; it has poor effect on methicillin-resistant Staphylococcus. According to the results of in vitro tests, Chlamydia, Staphylococcus aureus and Neisseria gonorrhoeae will develop resistance to this product. Combined with doxycycline, it has a synergistic effect on Neisseria gonorrhoeae; combined with isoniazid, its effect on Mycobacterium tuberculosis far exceeds that of rifampicin and isoniazid. Its mechanism of action is the same as that of rifampicin, which is to firmly bind to the subunit of DNA-dependent RNA polymerase, inhibit the synthesis of bacterial RNA, prevent the enzyme from connecting to DNA, thereby blocking the RNA transcription process and stopping the synthesis of DNA and protein. Animal experiments have shown that this product has certain liver toxicity and teratogenic effects on the fetus.